Based on the aggregated intelligence of 115,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) has earned a respected four-star ranking. While five-star stocks have been the best performers, our data has shown that four-star stocks still outshine the market by a significant margin and shouldn't be taken lightly; conversely, low-rated stocks have woefully lagged the market average.

With that in mind, let's take a closer look at Bristol-Myers' business, and see what CAPS investors are saying about the stock right now.

Bristol-Myers facts

Headquarters (Founded)

New York, N.Y. (1887)

Market Cap

$37.19 billion

Industry

Drug Manufacturing

TTM Revenue

$20.91 billion

Management

CEO James Cornelius (since September 2006)

CFO Jean-Marc Huet (since March 2008)

Return on Equity (average last three years)

18.73%

Competitors

Merck (NYSE:MRK),

Eli Lilly (NYSE:LLY)

CAPS members bullish on BMY also bullish on

Johnson & Johnson (NYSE:JNJ),

Pfizer (NYSE:PFE)

CAPS members bearish on BMY also bearish on

General Motors (NYSE:GM),

Microsoft (NASDAQ:MSFT)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, 92% of the 203 All-Star members who have rated Bristol-Myers believe the stock will outperform the S&P 500 going forward. These bulls include jvgarrison and stockdoc00, both of whom are ranked in the top 25% of our community.

In June, jvgarrison wrote that Bristol-Myers is "Another profitable company with a much above average dividend, and a potential takeover target due to its strong pipeline."

A more recent pitch from stockdoc00 last month shares that bullish sentiment, elaborating on the stock's downturn-defensive qualities:

As safe as they come in this industry. While it has potential challenges with patent expirations especially with Plavix, it has an underrated pipeline, strong balance sheet and a solid, dependable 5% dividend (hasn't missed a dividend payment in over 50 years!). In this uncertain market, this is stock that you can buy and sleep easy on.

What do you think about Bristol-Myers, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 115,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

On Oct. 7, 2008, Fool co-founder David Gardner and his Motley Fool Pro team invested $1 million in a portfolio designed to help you make money in any market. In the coming weeks, the team, relying heavily on proprietary CAPS "community intelligence" data, will establish long and short positions in a broad range of securities, including common stocks, publicly traded put and call options, and exchange-traded funds. To learn more about Motley Fool Pro and to receive a private invitation to join, simply enter your email address in the box below. 

Foolish contributor Brian Pacampara owns no position in any of the companies mentioned. Eli Lilly, Johnson & Johnson, and Pfizer are Motley Fool Income Investor recommendations. Pfizer and Microsoft are Inside Value picks. The Fool's disclosure policy always gets a perfect score.